




Expert Pediatric Drug Development

Delivering a Single Source Model for Preclinical and Clinical Development of Safe and Effective Medicines for Children



PHARMACOMETRICS		
Therapeutic Area	# of Studies	Study Phase
Oncology	38	Pre-Clinical - Ph III
Neurology	4	Ph I, II & III
Cardiology	11	Ph I & II
Diabetes	1	Ph II
Infectious Disease	11	Ph I, II & III
Urology	5	Ph I & II
Respiratory	2	Ph I & III
Inflammation	2	Ph I & II
CNS	22	Pre-Clinical - Ph III
Ophthalmology	2	Pre-Clinical - Ph I
Gastroenterology	3	Ph II & Ph IV
Dermatology	5	Ph I & II
Pain	6	Ph I - Ph IV

PEDIATRIC FORMULATION		
Therapeutic Area	# of Studies	Study Phase
CNS	4	Ph I & II
Dermatology	3	Ph II
Gastroenterology	1	Ph II

PEDIATRIC REGULATORY AFFAIRS		
Therapeutic Area	# of Studies	Study Phase
Cardiology	2	Ph I & II
Oncology	2	Ph I
CNS	4	Ph I & II
Dermatology	9	Ph I, II & III
Gastroenterology	4	Ph I, II & III
Infectious Disease	1	Ph II
Inflammation	1	Ph I
Pain	2	Ph II

JUVENILE TOXICOLOGY		
Therapeutic Area	# of Studies	Study Phase
Cardiology	1	Ph I
CNS	2	Ph I & II
Dermatology	3	Ph II
Gastroenterology	1	Ph II
Infectious Disease	1	Ph II

About Synteract

Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. It has contributed to more than 240 product approvals. Synteract offers a notable depth of expertise in oncology, general medicine, dermatology, and neuroscience indications, as well as rare and orphan, pediatric, and immunotherapy studies.

For more information on how we can support your clinical trial, please visit www.synteract.com/Therapeutic-Expertise/Pediatrics or ContactUs@synteract.com.

Synteract.com

BRINGING CLINICAL TRIALS TO LIFE™